Janux Therapeutics (JANX) Other Accumulated Expenses (2020 - 2026)
Janux Therapeutics (JANX) reported Other Accumulated Expenses of $841000.0 for Q1 2026, down 9.08% year-over-year from $925000.0 in Q1 2025, and down 10.91% quarter-over-quarter from $944000.0 in Q4 2025.
Janux Therapeutics (JANX) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has 7 years of Other Accumulated Expenses data on file, last reported at $841000.0 in Q1 2026.
- Other Accumulated Expenses for Q1 2026 came in at $841000.0, down 9.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $841000.0 (down 9.08% YoY), and the FY2025 annual result was $944000.0, up 2.83% from the prior year.
- Other Accumulated Expenses slipped to $841000.0 in Q1 2026 per JANX's latest filing, from $944000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $1.0 million in Q2 2023 and troughed at $332000.0 in Q1 2022.
- A 5-year average of $699529.4 and a median of $718000.0 in 2024 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses soared 194.52% in 2023, then declined 29.75% in 2024.
- A 5-year view of Other Accumulated Expenses shows it stood at $623000.0 in 2022, then retreated by 11.88% to $549000.0 in 2023, then surged by 67.21% to $918000.0 in 2024, then advanced by 2.83% to $944000.0 in 2025, then fell by 10.91% to $841000.0 in 2026.
- Business Quant data shows JANX's Other Accumulated Expenses at $841000.0 in Q1 2026, $944000.0 in Q4 2025, and $551000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Janux Therapeutics | 892.99 Mn | 892.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 841,000.00 |
| Dec 31, 2025 | 944,000.00 |
| Sep 30, 2025 | 551,000.00 |
| Jun 30, 2025 | 587,000.00 |
| Mar 31, 2025 | 925,000.00 |
| Dec 31, 2024 | 918,000.00 |
| Sep 30, 2024 | 778,000.00 |
| Jun 30, 2024 | 718,000.00 |
| Mar 31, 2024 | 805,000.00 |
| Dec 31, 2023 | 549,000.00 |
| Sep 30, 2023 | 609,000.00 |
| Jun 30, 2023 | 1.02 Mn |
| Mar 31, 2023 | 734,000.00 |
| Dec 31, 2022 | 623,000.00 |
| Sep 30, 2022 | 609,000.00 |
| Jun 30, 2022 | 347,000.00 |
| Mar 31, 2022 | 332,000.00 |
| Dec 31, 2021 | 478,000.00 |
| Sep 30, 2021 | 517,000.00 |
| Jun 30, 2021 | 199,000.00 |